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A commentary on
Nucleoside reverse transcriptase
inhibitors possess intrinsic anti-
inflammatory activity
by Fowler, B. J., Gelfand, B. D., Kim,
Y., Kerur, N., Tarallo, V., Hirano, Y.,
et al. (2014). Science 346, 1000–1003. doi:
10.1126/science.1261754
Nucleoside reverse transcriptase inhibitors
(NRTIs) have been the backbones of HIV
therapy since introduced in the late 1980s.
These HIV drugs act by blocking the viral
reverse transcriptase activity that is crucial
in the HIV life cycle. In a recent study pub-
lished by Science, Fowler et al. (2014) have
shown that such antiretroviral agents can
inhibit P2X7 receptor (P2X7R)-mediated
Alu RNA-induced activation of caspase-1
in retinal pigment epithelial (RPE) cells
and ATP-induced activation of caspase-
1 in macrophage cells, independently of
reverse transcriptase inhibition.
P2X7R belongs to the ATP-gated
ion channel P2XR family and is highly
expressed in immune and epithelial cells
(North, 2002). P2X7R activation requires
submillimolar ATP and the P2X7R is thus
well placed as a molecular sensor detecting
extracellular ATP, an endogenous danger
associated with tissue damage and inflam-
mation. It is firmly established that P2X7R
in macrophage cells plays an essential
role in mediating ATP-induced assem-
bly of the multi-protein complex NLRP3
inflammasome, activation of caspase-1
and generation of interleukin (IL)-1β, a
key proinflammatory cytokine in innate
immunity. Such signaling mechanisms, if
not resolved in time, can lead to numerous
inflammatory conditions. P2X7R antago-
nists have been passionately exploited as
anti-inflammation therapeutics. Several
drug discovery programs have discovered
a number of structurally novel compounds
as P2X7R antagonists with drug-like prop-
erties. Such compounds show promising
anti-inflammation efficacy in preclinical
studies using animal models, but recent
clinical trials treating rheumatoid arthritis
have been rather disappointing. Non-
coding Alu-derived RNAs are accumulated
in the retinal pigment epithelium, and Alu
RNAs-induced RPE cell death underlies
geographic atrophy and choroidal neo-
vascularization, two distinctive forms
of aged-related macular degeneration
responsible for loss of vision in the elderly
people. The same group shows in another
study that Alu RNAs can stimulate the
P2X7R activity via undefined mechanisms
to activate the NLRP3 inflammasome
and caspase-1. In this recent study, they
provide evidence to show that NRTIs
inhibit P2X7R-mediated activation of
caspase-1 in RPE cells and in LPS-primed
macrophage cells induced by Alu RNAs
and ATP, respectively. Furthermore, they
have demonstrated that such HIV drugs
exhibit significant anti-inflammation effi-
cacy in mouse models of geographic
atrophy, choroidal neovascularization,
graft-vs-host diseases, and sterile liver
inflammation. This is a truly exciting find-
ing as many clinically proved HIV drugs
can be readily tested as anti-inflammation
therapeutics.
P2X7R, like all other P2XRs, func-
tions as a channel that opens upon brief
stimulation to permeate small physiolog-
ical cations (North, 2002). However, it is
known from the conception of the P2XR
research that P2X7R is functionally excep-
tional; prolonged activation can induce a
large pore that passes molecules in size
of up to 900 Da and can eventually lead
to cell death, thus formerly named the
cytolytic P2Z receptor (Surprenant et al.,
1996). Nearly 20 years on from identifica-
tion as the last member of the P2XR family,
the molecular mechanisms underpinning
such striking plasticity in permeability is
still puzzling. A recent study unequivo-
cally demonstrates that the P2X7R small
cationic channel can dilate to become the
large pore (Browne et al., 2013). There
is compelling evidence to support that
P2X7R-dependent formation of the intrin-
sic large pore in macrophage cells engages
pannexin-1, and particularly requires an
interaction of pannexin-1 with the unique
C-terminus of the P2X7R (Pelegrin and
Surprenant, 2006; Sorge et al., 2012). The
genes encoding the mammalian P2X7Rs
and particularly human P2X7R are prolific
with non-synonymous single nucleotide
polymorphisms (NS-SNP), and NS-SNP
mutations can significantly alter the small
cationic channel, the large pore, or both
functionalities. For example, the NS-SNP
P451L mutation in the C-terminus of the
mouse P2X7R totally abolishes the large
pore formation without altering the small
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cationic channel function in macrophage
cells (Sorge et al., 2012). Furthermore,
the mice expressing P2X7R containing
Leu451 are considerably less susceptible to
inflammatory pain compared to the mice
expressing the P2X7R harboring Pro451,
explicitly indicating that the large pore
but not the small cationic channel is cru-
cial in dictating the severity of inflam-
matory disease. Such notion is echoed
by the intriguing mechanisms of inhibi-
tion of the HIV drugs revealed in the
study by Fowler et al. (2014). P2X7R acti-
vation is required for both Alu RNAs-
induced caspase-1 activation in RPE cells
and ATP-induced caspase-1 activation in
LPS-primed macrophage cells. Blockage of
the P2X7R would be the simplest answer,
but the truth seems never so straight-
forward. In HEK293 cells heterologously
expressing rat or mouse P2X7R, A438079,
a P2X7R antagonist, completely prevented
the small cationic channel and large pore.
In striking contrast, the HIV drug tested
reduced partially but significantly the large
pore formation without effect on the
small cationic channel, supporting pre-
ferred targeting of the large pore (Fowler
et al., 2014). This is consistent with no
effect on Alu RNAs-induced caspase-1
activation in RPE cells of calmidazolium,
a P2X7R inhibitor known to prefer-
entially block the open small cationic
channel but not the large pore or cell
death. Surprisingly, Alu RNAs-induced
caspase-1 activation remained unaltered
in RPE cells from the pannexin-1 defi-
cient mice, suggesting that pannexin-1 is
not required as reported previously for
ATP-induced caspase-1 activation in LPS-
primed macrophage cells (Qu et al., 2011).
The intriguing twist was that Alu RNAs-
induced capase-1 activation was abolished
by 10Pan, a mimetic peptide thought to
block pannexin-1 dependent large pore
formation in macrophage cells (Pelegrin
and Surprenant, 2006; Sorge et al., 2012).
Such remarkable inhibition was how-
ever attributed to be a non-specific effect
on formation of a large pore indepen-
dent of pannexin-1 (Fowler et al., 2014).
This interpretation requires more vigorous
examination, for example, using RPE cells
from the mice expressing the P2X7R with
Pro451 or Leu451 and using the Pro451-
containing competing peptide to disrupt
the interaction between pannexin-1 and
P2X7R, as shown in the aforementioned
study (Sorge et al., 2012). Regardless, these
recent studies, examining HIV drug inhi-
bition of P2X7R-mediated caspase-1 acti-
vation (Fowler et al., 2014) and P2X7R-
mediated inflammatory pain (Sorge et al.,
2012), provide consistent evidence to sug-
gest that the large pore functionality
is more crucial than the small cationic
channel in P2X7R-mediated inflamma-
tion. Such a disease mechanistic insight is
fundamentally important that needs to be
borne in mind for development and cer-
tainly clinical trials of anti-inflammation
therapeutics targeting the P2X7R.
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